Journal
CHEMMEDCHEM
Volume 14, Issue 6, Pages 615-620Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201900019
Keywords
antitumor agents; indazoles; MEK4; kinases; prostate cancer
Categories
Funding
- US National Cancer Institute (NCI) [R01CA188015]
- Chicago Biomedical Consortium
- US National Science Foundation (NSF) [DGE-1324585]
- Searle Funds at The Chicago Community Trust
- Cancer Center Support Grant from NCI [P30CA060553]
Ask authors/readers for more resources
Herein we report the discovery of a novel series of highly potent and selective mitogen-activated protein kinase kinase 4 (MEK4) inhibitors. MEK4 is an upstream kinase in MAPK signaling pathways that phosphorylates p38 MAPK and JNK in response to mitogenic and cellular stress queues. MEK4 is overexpressed and induces metastasis in advanced prostate cancer lesions. However, the value of MEK4 as an oncology target has not been pharmacologically validated because selective chemical probes targeting MEK4 have not been developed. Optimization of this series via structure-activity relationships and molecular modeling led to the identification of compound 6 ff (4-(6-fluoro-2H-indazol-3-yl)benzoic acid), a highly potent and selective MEK4 inhibitor. This series of inhibitors is the first of its kind in both activity and selectivity and will be useful in further defining the role of MEK4 in prostate and other cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available